IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding
TLDR
A new web-server tool estimates Ki values from experimentally determined IC50 values for inhibitors of enzymes and of binding reactions between macromolecules and ligands to enable end users to help gauge the quality of the underlying assumptions used in these calculations.Abstract:
A new web-server tool estimates Ki values from experimentally determined IC50 values for inhibitors of enzymes and of binding reactions between macromolecules (e.g. proteins, polynucleic acids) and ligands. This converter was developed to enable end users to help gauge the quality of the underlying assumptions used in these calculations which depend on the type of mechanism of inhibitor action and the concentrations of the interacting molecular species. Additional calculations are performed for nonclassical, tightly bound inhibitors of enzyme-substrate or of macromolecule-ligand systems in which free, rather than total concentrations of the reacting species are required. Required userdefined input values include the total enzyme (or another target molecule) and substrate (or ligand) concentrations, the Km of the enzyme-substrate (or the Kd of the target-ligand) reaction, and the IC50 value. Assumptions and caveats for these calculations are discussed along with examples taken from the literature. The host database for this converter contains kinetic constants and other data for inhibitors of the proteolytic clostridial neurotoxins (http:// botdb.abcc.ncifcrf.gov/toxin/kiConverter.jsp).read more
Citations
More filters
Journal ArticleDOI
DeepDTA: deep drug–target binding affinity prediction
TL;DR: A deep learning based model that uses only sequence information of both targets and drugs to predict DT interaction binding affinities is proposed, outperforming the KronRLS algorithm and SimBoost, a state‐of‐the‐art method for DT binding affinity prediction.
Journal ArticleDOI
Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase
Georg Petzold,Eric S. Fischer,Eric S. Fischer,Eric S. Fischer,Nicolas H. Thomä,Nicolas H. Thomä +5 more
TL;DR: This study provides a mechanistic explanation for the selective efficacy of lenalidomide in del(5q) MDS therapy and predicts that high-affinity protein–protein interactions induced by small molecules will provide opportunities for drug development, particularly for targeted protein degradation.
Journal ArticleDOI
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
Longchuan Bai,Haibin Zhou,Renqi Xu,Yujun Zhao,Krishnapriya Chinnaswamy,Donna McEachern,Jianyong Chen,Chao Yie Yang,Zhaomin Liu,Mi Wang,Liu Liu,Hui Jiang,Bo Wen,Praveen Kumar,Jennifer L. Meagher,Duxin Sun,Jeanne A. Stuckey,Shaomeng Wang +17 more
TL;DR: SD-36 achieves complete and long-lasting tumor regression in multiple xenograft mouse models at well-tolerated dose schedules and is a promising cancer therapeutic strategy.
Journal ArticleDOI
Fluorescence Polarization Assays in Small Molecule Screening
Wendy A. Lea,Anton Simeonov +1 more
TL;DR: In addition to its continued utilization in high-throughput screening, FP has expanded into new disease and target areas and has been marked by increased use of labeled small molecule ligands for receptor-binding studies.
Journal ArticleDOI
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.
Quinlan L. Sievers,Quinlan L. Sievers,Georg Petzold,Richard D. Bunker,Aline Renneville,Aline Renneville,Mikolaj Slabicki,Mikolaj Slabicki,Mikolaj Slabicki,Brian J. Liddicoat,Brian J. Liddicoat,Wassim Abdulrahman,Tarjei S. Mikkelsen,Benjamin L. Ebert,Benjamin L. Ebert,Benjamin L. Ebert,Nicolas H. Thomä +16 more
TL;DR: The human ZF “degrome” is defined in the context of thalidomide, lenalidomid, and pomalidomides to characterize the ZF-drug-CRBN interaction structurally and functionally and determine whether different thalidmide analogs degrade distinct ZFs.
References
More filters
Journal ArticleDOI
Estimating KI values for tight binding inhibitors from dose-response plots
TL;DR: A simple method by which the K i value of tight binding inhibitors of enzymes can be calculated directly from the IC 50 value determined from graphical analysis of dose-response curves is described.
Journal ArticleDOI
The protein structure initiative structural genomics knowledgebase
Helen M. Berman,John D. Westbrook,Margaret Gabanyi,Wendy Tao,Raship Shah,Kouranov Andrei Y,Torsten Schwede,Konstantin Arnold,Florian Kiefer,Lorenza Bordoli,Jürgen Kopp,Michael Podvinec,Paul D. Adams,Lester G. Carter,Wladek Minor,Rajesh Nair,Joshua La Baer +16 more
TL;DR: The Protein Structure Initiative Structural Genomics Knowledgebase (PSI SGKB) as mentioned in this paper was created to turn the products of the PSI structural genomics effort into knowledge that can be used by the biological research community to understand living systems and disease.
Journal ArticleDOI
The Protein Structure Initiative Structural Genomics Knowledgebase
Margaret Gabanyi,John D. Westbrook,Wendy Tao,Raship Shah,Kouranov Andrei Y,Torsten Schwede,Konstantin Arnold,Florian Kiefer,Lorenza Bordoli,Michael Podvinec,Jürgen Kopp,Paul D. Adams,Lester G. Carter,Wladek Minor,Rajesh Nair,Joshua La Baer,Helen M. Berman +16 more
TL;DR: This resource provides central access to structures in the Protein Data Bank (PDB), along with functional annotations, associated homology models, worldwide protein target tracking information, available protocols and the potential to obtain DNA materials for many of the targets.
Journal ArticleDOI
Calculation of inhibitor Ki and inhibitor type from the concentration of inhibitor for 50% inhibition for Michaelis-Menten enzymes
TL;DR: Modifications of the Michaelis-Menten equation for treatment of inhibitors can allow both the determination of the type of inhibition (competitive, noncompetitive, and uncompetitive) and the Ki for the inhibitor.
Journal ArticleDOI
National Institute of Allergy and Infectious Diseases bioinformatics resource centers: new assets for pathogen informatics.
John M. Greene,Frank H. Collins,Elliot J. Lefkowitz,David S. Roos,Richard H. Scheuermann,Bruno W. S. Sobral,Rick Stevens,Owen White,Valentina Di Francesco +8 more
TL;DR: The National Institute of Allergy and Infectious Diseases (NIAID) began a new bioinformatic venture in July 2004 intended to integrate the vast amount of genomic and other biological data that are both available and being produced by the rapid increase in biodefense research.